[
  {
    "ts": null,
    "headline": "Moderna Inc. stock underperforms Monday when compared to competitors",
    "summary": "Moderna Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=fa29af34a23ccb2c905c160ea51c08ef3b8cb71831dd6561de10ac502f2a65a3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731342720,
      "headline": "Moderna Inc. stock underperforms Monday when compared to competitors",
      "id": 131432201,
      "image": "",
      "related": "MRNA",
      "source": "MarketWatch",
      "summary": "Moderna Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=fa29af34a23ccb2c905c160ea51c08ef3b8cb71831dd6561de10ac502f2a65a3"
    }
  },
  {
    "ts": null,
    "headline": "Moderna’s mRESVIA vaccine gains Health Canada approval",
    "summary": "The approval by Health Canada is supported by the outcomes from the ConquerRSV Phase III study.",
    "url": "https://finnhub.io/api/news?id=18e96ae656bb544e7b0b4b9dfe8f62431675f26e9da422ba691719c9f0a65fcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731325361,
      "headline": "Moderna’s mRESVIA vaccine gains Health Canada approval",
      "id": 131300263,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/11/Pharma2-Moderna-Shutterstock_2324162019.jpg",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The approval by Health Canada is supported by the outcomes from the ConquerRSV Phase III study.",
      "url": "https://finnhub.io/api/news?id=18e96ae656bb544e7b0b4b9dfe8f62431675f26e9da422ba691719c9f0a65fcd"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: share price down, a broker's analysis",
    "summary": "Moderna is down nearly 6% in London, after Oddo BHF reduced its price target from $96 to $86.The broker reports that despite a qualitative Q3, the stock remained under pressure at the end of the...",
    "url": "https://finnhub.io/api/news?id=8f4bbff1e3f5dd8de3b6c4f9a94d605fd90c9b1326eb10f54a29f58ae43ae42d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731324265,
      "headline": "Moderna: share price down, a broker's analysis",
      "id": 131286496,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "Moderna is down nearly 6% in London, after Oddo BHF reduced its price target from $96 to $86.The broker reports that despite a qualitative Q3, the stock remained under pressure at the end of the...",
      "url": "https://finnhub.io/api/news?id=8f4bbff1e3f5dd8de3b6c4f9a94d605fd90c9b1326eb10f54a29f58ae43ae42d"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older",
    "summary": "CAMBRIDGE - Moderna, Inc. today announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in...",
    "url": "https://finnhub.io/api/news?id=7e3da145f8fdc2b8f7c6ab673db8dffe57135cb70971578a0337ce9967f0f054",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731321314,
      "headline": "Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older",
      "id": 131285614,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "CAMBRIDGE - Moderna, Inc. today announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in...",
      "url": "https://finnhub.io/api/news?id=7e3da145f8fdc2b8f7c6ab673db8dffe57135cb70971578a0337ce9967f0f054"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: Oddo BHF lowers its price target",
    "summary": "Oddo BHF maintains its 'outperform' rating on Moderna shares, with a price target reduced from $96 to $86. The broker reports that, despite a qualitative Q3, the share remained under pressure at the...",
    "url": "https://finnhub.io/api/news?id=386a2548d020d65be5fb1e30784a6ec161c6a64a8d335217ece99ac1a6dac07f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731297128,
      "headline": "Moderna: Oddo BHF lowers its price target",
      "id": 131281741,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "Oddo BHF maintains its 'outperform' rating on Moderna shares, with a price target reduced from $96 to $86. The broker reports that, despite a qualitative Q3, the share remained under pressure at the...",
      "url": "https://finnhub.io/api/news?id=386a2548d020d65be5fb1e30784a6ec161c6a64a8d335217ece99ac1a6dac07f"
    }
  }
]